ProSciento, Inc. Company Profile

Background

Overview

ProSciento, Inc. is a specialized clinical research organization (CRO) headquartered in San Diego, California, focusing exclusively on metabolic diseases, including diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Established in 2003, the company has conducted over 300 metabolic clinical projects, positioning itself as a leader in early-phase clinical trials for metabolic conditions.

Mission and Vision

ProSciento's mission is to advance the global development of novel therapeutics for metabolic diseases. Its vision is to be the leading clinical research and development organization in diabetes, obesity, and NASH, internationally recognized for the relevance and quality of its work.

Industry Significance

The company is widely recognized for its scientific and therapeutic expertise, unparalleled experience in metabolism, and utilization of advanced, specialized methodologies for metabolic clinical research. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with a comprehensive and scalable portfolio of services, from strategic planning through completion of early-phase clinical drug and device development.

Key Strategic Focus

Core Objectives

ProSciento aims to provide customized clinical research services for multinational, early development clinical trial programs, offering clients an advantage in the rapidly evolving landscape of metabolic drug and device development.

Areas of Specialization

The company specializes in early-phase clinical trials for metabolic diseases, including diabetes, obesity, and NASH. ProSciento offers a comprehensive portfolio of services to enable the rapid, efficient, and cost-effective validation and development of novel drugs and devices for these conditions.

Key Technologies Utilized

ProSciento employs advanced methodologies, including automated glucose clamp studies, to enhance the reliability and precision of metabolic clinical trials. The company also utilizes specialized clinical research methodologies and has a global network of advanced method hubs to support its research initiatives.

Primary Markets Targeted

The primary markets targeted by ProSciento include the United States, Europe, Australia, South America, and Asia, with a focus on regions with a high prevalence of metabolic diseases and a strong presence of biopharmaceutical companies.

Financials and Funding

Funding History

In September 2020, ProSciento closed a growth financing round from 1315 Capital, a healthcare investment firm. The funds raised were intended to support the expansion of the company's CRO operations and the continued growth of its patient access solutions, including the NASH PASS® program.

Total Funds Raised

The total funds raised by ProSciento amount to $2 million from the growth financing round in 2020.

Notable Investors

The notable investor in this funding round was 1315 Capital, a healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty therapeutics companies.

Utilization of Capital

The capital raised was intended to support the expansion of ProSciento's CRO operations and the continued growth of its patient access solutions, including the NASH PASS® program.

Pipeline Development

ProSciento has been involved in the development of numerous metabolic drugs and devices, supporting their progression from early-phase clinical trials through to market approval. The company's expertise spans various drug classes and therapeutic areas within the metabolic disease spectrum.

Technological Platform and Innovation

Proprietary Technologies

ProSciento utilizes proprietary technologies such as the NASH PASS® program, a patient access solution designed to accelerate clinical trial recruitment for NASH studies.

Significant Scientific Methods

The company employs advanced scientific methodologies, including automated glucose clamp studies, to enhance the precision and reliability of metabolic clinical trials.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed in the available information, ProSciento's commitment to scientific excellence and innovation suggests an openness to integrating advanced technologies to improve clinical research processes.

Leadership Team

Key Executives

Marcus Hompesch, M.D.: Chief Executive Officer and Chairman of the Board. Dr. Hompesch has been instrumental in leading ProSciento's growth and strategic direction.

Megan McCormick: Chief Operating Officer. Appointed in June 2025, Ms. McCormick oversees the company's global operations, ensuring efficient execution of clinical trials and research initiatives.

Pete Nieto: Vice President of Business Development. Joined in May 2018, Mr. Nieto is responsible for expanding ProSciento's global sales and developing strategic biopharma partnerships.

Leadership Changes

Megan McCormick: Appointed as Chief Operating Officer in June 2025, Ms. McCormick brings extensive experience in clinical operations and research management.

Competitor Profile

Market Insights and Dynamics

The clinical research organization (CRO) market, particularly in the metabolic disease sector, is characterized by a growing demand for specialized services due to the increasing prevalence of conditions like diabetes, obesity, and NASH. This demand drives competition among CROs to offer comprehensive, efficient, and innovative solutions.

Competitor Analysis

ProSciento's key competitors include large CROs such as IQVIA, ICON plc, and Charles River Laboratories, which offer a broad range of clinical research services across various therapeutic areas. However, ProSciento differentiates itself by its exclusive focus on metabolic diseases, providing specialized expertise and tailored services that set it apart in the competitive landscape.

Strategic Collaborations and Partnerships

ProSciento has established strategic partnerships to enhance its research capabilities and expand its global reach. Notable collaborations include:

LMC Diabetes & Endocrinology: In June 2016, ProSciento and LMC formed a strategic alliance to conduct cross-border, multi-site clinical research for diabetes and related metabolic disorders, leveraging LMC's extensive network of clinical research sites in Canada.

OWL Metabolomics: In 2015, ProSciento and OWL Metabolomics formed a strategic collaboration focused on accelerating NASH clinical trial recruitment, combining ProSciento's clinical research expertise with OWL's diagnostic assays for liver diseases.

Operational Insights

ProSciento's strategic focus on metabolic diseases allows it to maintain a competitive edge by offering specialized services that cater to the unique challenges of this therapeutic area. The company's global network of clinical trial sites and advanced method hubs enables efficient patient recruitment and data collection, further enhancing its operational capabilities.

Strategic Opportunities and Future Directions

ProSciento is well-positioned to capitalize on the growing demand for specialized clinical research services in the metabolic disease sector. Opportunities for expansion include increasing its presence in emerging markets, enhancing its technological infrastructure, and continuing to build strategic partnerships to strengthen its market position.